J-LEAPS peptide and LEAPS dendritic cell vaccines

Ken S. Rosenthal, Patricia Taylor, Daniel H. Zimmerman

Research output: Contribution to journalShort surveypeer-review

12 Scopus citations


The J-LEAPS vaccines contain a peptide from β-2-microglobulin covalently attached to disease-related peptides of 8-30 amino acids which contain a T cell epitope. The J-LEAPS vaccines can initiate a protective Th1 immune response or modulate an ongoing Th17 autoimmune response to the peptide. J-LEAPS vaccines activate and direct the nature of the subsequent immune response by promoting the maturation of precursor cells into a unique type of dendritic cell that produces interleukin 12, but not IL-1 or tumour necrosis factor, and presents the antigenic peptide to T cells. Adoptive transfer of JgD-LEAPS dendritic cells, matured with an anti-HSV-1 vaccine, promoted antigen-specific Th1 protection against lethal challenge with the virus. J-LEAPS peptide immunogens and J-LEAPS dendritic cell vaccines have potential applications for antimicrobial prevention and therapy, treatment of autoimmune diseases, and for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)203-213
Number of pages11
JournalMicrobial Biotechnology
Issue number2
StatePublished - Mar 2012
Externally publishedYes

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biochemistry
  • Applied Microbiology and Biotechnology


Dive into the research topics of 'J-LEAPS peptide and LEAPS dendritic cell vaccines'. Together they form a unique fingerprint.

Cite this